During the 2026 Yabuli Forum Summer Annual Meeting, during a conversation with Sina Technology, Dr. Zhu Jun, Executive Director and CEO of Fu Hong Hanlin, systematically explained the underlying logic of the company's “system going overseas” strategy. He shared his different paths to the sea. One type is “selling young seedlings” commonly in the industry — that is, early pipeline licensing. “The probability that it can actually be registered, approved, listed, and sold in the local country may not be higher than 10%”. Essentially, it is a short-term implementation of R&D capabilities. The other is the “system going overseas” that Fu Hong Han Lin insisted on. The ultimate goal is to obtain “long-term benefits.” The product has gone through complete clinical development from phase I to phase III, obtained key clinical research results, and was approved for marketing and sale in local countries. “Fuhong Hanlin can get its due share of sales every year, and this is not a year.”

During the 2026 Yabuli Forum Summer Annual Meeting, during a conversation with Sina Technology, Dr. Zhu Jun, Executive Director and CEO of Fu Hong Hanlin, systematically explained the underlying logic of the company's “system going overseas” strategy. He shared his different paths to the sea. One type is “selling young seedlings” commonly in the industry — that is, early pipeline licensing. “The probability that it can actually be registered, approved, listed, and sold in the local country may not be higher than 10%”. Essentially, it is a short-term implementation of R&D capabilities. The other is the “system going overseas” that Fu Hong Han Lin insisted on. The ultimate goal is to obtain “long-term benefits.” The product has gone through complete clinical development from phase I to phase III, obtained key clinical research results, and was approved for marketing and sale in local countries. “Fuhong Hanlin can get its due share of sales every year, and this is not a year.”